Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

This is a commonly used substance with well known effects, but that does not guarantee the substance will be safe. The safety profile has been established based on usage data commonly reported by others.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

DMT Also known as:

  • (2-Indol-3-ylethyl)dimethylamine
  • 1H-Indole-3-ethanamine, N,N-dimethyl-[ACD/Index Name]
  • 2-(1H-Indol-3-yl)-N,N-dimethylethanamin[German][ACD/IUPAC Name]
  • 2-(1H-Indol-3-yl)-N,N-dimethylethanamine[ACD/IUPAC Name]
  • 2-(1H-Indol-3-yl)-N,N-diméthyléthanamine[French][ACD/IUPAC Name]
  • DMT
  • Indole, 3-(2-(dimethylamino)ethyl)-
  • Indole, 3-[2- (dimethylamino)ethyl]-
  • Indole, 3-[2-(dimethylamino)ethyl]-
  • MFCD00055989[MDL number]
  • N,N-Dimethyl-1H-indole-3-ethanamine
  • N,N-dimethyl-1H-indole-3-ethylamine
  • N,N-DMT
  • tryptamine, dimethyl-
  • [2-(1H-Indol-3-yl)-ethyl]-dimethyl-
  • [2-(1H-indol-3-yl)ethyl]dimethylamine
  • [2-(1H-Indol-3-yl)-ethyl]-dimethyl-amine
  • 1H-INDOLE-3-ETHANAMINE,N,N-DIMETHYL
  • 1H-Indole-3-ethanamine,N,N-dimethyl-
  • 2-(1H-indol-3-yl)ethyl-dimethyl-amine
  • 2-(1H-indol-3-yl)-N,N-dimethyl-ethanamine
  • 2-(3-indolyl)ethyldimethylamine
  • 3-(2-(Dimethylamino)ethyl)-Indole
  • 3-(2-Dimethylaminoethyl) indole
  • 3-(2-dimethylaminoethyl)indole
  • 3-[2- (Dimethylamino)ethyl]-Indole
  • 3-[2-(dimethylamino)ethyl]indole
  • 5-22-10-00048 (Beilstein Handbook Reference)[Beilstein]
  • N N-DIMETHYL-1H-INDOLE-3-ETHYLAMINE
  • WLN: T56 BMJ D2N1&1

A popular and powerful psychedelic, typically used in two ways; either it is vapourised for a short ‘breakthrough’ experience, or it is taken in combination with an enzyme inhibitor for a long, intense trip (this is also known as ayahuasca or pharmahuasca).

Summary

Despite being one of the simplest psychedelic compounds, it is known for its unique ability to produce short-lived but intense visionary states and complete hallucinations. It is thought to produce its psychedelic effects by binding to serotonin receptors in the brain, although the precise mechanism is not fully understood. DMT is present in over 65 species of plants and has been identified as being a normal constituent of human metabolism and an endogenous neurotransmitter in certain rodents.

Its presence is also known to be widespread throughout the plant kingdom. Although various theories have been postulated, its neurobiological function has yet to be determined. Depending on the dosage and method of administration, the effects of DMT can range from mild psychedelic states to powerfully immersive life-altering experiences which are often described as the ultimate displacement from ordinary consciousness in which users report experiencing ineffable spiritual realms or alternate dimensions.

When vaporized or smoked, DMT produces short-lived effects with a very rapid onset that is sometimes described as an “inconceivably high-speed rollercoaster ride. " When ingested in combination with a MAOI or RIMA agent, it becomes active orally and significantly longer lasting, immersive, and interactive in nature: this combination is known as ayahuasca. Ayahuasca brews have been used traditionally in South America since at least around the year 1500.

Unlike most highly prohibited substances, DMT is not considered to be addictive or toxic by the scientific community. Nevertheless, unpredictable adverse reactions such as uncontrollable anxiety, delusions and psychosis can always occur, particularly among those predisposed to mental disorders. While these negative reactions or “bad trips” can often be attributed to user inexperience or improper preparation of set and setting, they have been known to happen spontaneously among even highly experienced users as well.

It is therefore highly advised to use harm reduction practices if using this substance.

History

In 1955, a team of American chemists led by Evan Horning isolated and formally identified DMT in the seeds and pods of Anadenanthera peregrina. Since 1955, DMT has been found in a host of organisms: in at least fifty plant species belonging to ten families, and in at least four animal species, including one gorgonian and three mammalian species.

Chemistry

DMT

DMT

Tryptamines share a core structure consisting of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain.

DMT contains two methyl groups (CH3-) bound to the terminal amine RN at the end of this chain. DMT has many homologs and analogs from base tryptamines like MET and DPT, to four and five position substituted variants such as 4-PO-DMT (psilocybin), 4-AcO-DMT (psilacetin), 5-HO-DMT (bufotenin), and 5-MeO-DMT. DMT is a white, pungent-smelling, crystalline solid.

It is insoluble in water, but soluble in organic solvents and aqueous acids.

Common NameDimethyltryptamine
Systematic nameDimethyltryptamine
FormulaC_{12}H_{16}N_{2}
SMILESCN(C)CCc1c[nH]c2c1cccc2
Std. InChiInChI=1S/C12H16N2/c1-14(2)8-7-10-9-13-12-6-4-3-5-11(10)12/h3-6,9,13H,7-8H2,1-2H3
Std. InChiKeyDMULVCHRPCFFGV-UHFFFAOYSA-N
Avg. Mass188.2688 Da
Molecular Weight188.2688
Monoisotopic Mass188.131348 Da
Nominal Mass188
ChemSpider ID5864

Subscribe for the latest updates

Dose Chart

Vapourised
Threshold5-10mg
Light10-15mg
Common15-25mg
Strong25-35mg
Heavy35mg+
Insufflated
Light10-25mg
Common25-50mg
Strong50-125mg+
Intravenous
Light10-15mg
Common15-25mg
Strong25-40mg

Duration Chart

Vaporized/smoked
Onset0-2 minutes
Duration3-10 minutes
After-effects15-60 minutes

Interactions

Caution

  1. Cannabis
    • Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
  2. Amphetamines
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  3. Cocaine
    • Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences

Dangerous

  1. Tramadol
    • Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.

No Synergy

  1. Caffeine
  2. Opioids

Auditory Effects

  • Enhancements - Enhancements of one's auditory acuity, often following the end of the experience, have been reported in clinical studies with intravenously-administered DMT.
  • Distortions
  • Hallucinations

Psychological Effects

Pharmacological Effects

DMT’s psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. In addition to this, N,N-dimethyltryptamine is believed to be an endogenous ligand for the sigma receptor. However, the significance of the sigma-1 receptor remains the subject of ongoing scientific research.

Physical Effects

Sensory Effects

  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Subjective Effects

DMT in its smokeable form is reported to be the least mentally inebriating psychedelic. It is due to a lack of perceived intoxication that many people describe DMT as a genuine experience that is actually happening to them. It is worth noting that many people report that smoked DMT is extremely clear-headed in its style and tends to produce less personal insight in comparison to orally active psychedelics such as ayahuasca, LSD and psilocybin due to its short-acting nature.

Visual Effects

Enhancements

Distortions

Geometry

The visual geometry encountered can be described as more similar in appearance to that of psilocin than LSD. It can be comprehensively described through its variations as intricate in complexity, abstract in form, equally organic and digital in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, equal in sharp and soft edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in its intensity. At higher doses, it is significantly more likely to result in states of level 8B visual geometry over level 8A.

The geometry present with smokeable DMT is considered by many to be the most profoundly intricate and complex set of visual geometry found within the entirety of the psychedelic experience. In comparison to orally active DMT (ayahuasca), it is significantly more digital in appearance and contains a colour scheme which is similar to LSD and a structured style that resembles a high dose of psilocin (4-HO-DMT).

Hallucinatory states

DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic. These effects include:

Legal Status

Internationally, DMT is classified as a Schedule I controlled substance under the United Nations 1971 Convention on Psychotropic Substances, meaning that international trade in DMT is supposed to be closely monitored and its use is supposed to be restricted to scientific research and medical use. Natural materials containing DMT, including ayahuasca, are not regulated under the 1971 Psychotropic Convention.

  • Australia: DMT is controlled under Schedule 9 of the Poisions Standard.
  • Austria: DMT is illegal to possess, produce and sell under the SMG (Suchtmittelgesetz Österreich).
  • Brazil: DMT is illegal to possess, produce and sell under Portaria SVS/MS nº 344. Rules are relaxed regarding religious use.
  • Canada: DMT is a Schedule III controlled substance.
  • Denmark: DMT is a Category B controlled substance.
  • Estonia: DMT is a Schedule I controlled substance.
  • France: DMT is classified as a narcotic.
  • Germany: DMT is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of January 24, 1974. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
  • Italy: DMT is a Schedule I controlled substance.
  • Hungary: DMT is illegal to possess, produce and sell.
  • Ireland: DMT is controlled under the Misuse of Drugs Acts, 1977.
  • Latvia: DMT is a Schedule I controlled substance.
  • The Netherlands: DMT is classified as a Lijst 1 (List I) controlled substance under the Opiumwet (Opium Law).
  • New Zealand: DMT is classified in New Zealand as a Class A controlled substance under the Misuse of Drugs Act 1975.
  • Norway: DMT is a Schedule I controlled substance.
  • Russia: DMT is a список I (List I) contolled substance. It is illegal to possess, produce and sell.
  • Serbia: DMT is a List 4 controlled substance.
  • Sweden: DMT is controlled under Förteckning I (Schedule 1).
  • United Kingdom: DMT is a Class A controlled substance.
  • United States: DMT is a Schedule I controlled substance. Rules are relaxed regarding religious use, however. In the US, dried root bark of Mimosa hostilis had been considered a "grey area" item for a long time. However, recent efforts by the DEA appear to be focusing on eliminating internet sales of the bark, citing 21 USC § 841, which states that "(IV) any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subclauses (I) through (III)" is also considered an illegal substance. Many USA based vendors have since been stocking Acacia confusa bark as a result due to its very similar alkaloid content.
  • Sources

    References

    1. Nichols, David E. (2016). Barker, Eric L., ed. "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. :10.1124/pr.115.011478.  1521-0081.  0031-6997.
    2. Ott, Jonathan (1994). Ayahuasca Analogues: Pangæan Entheogens (1st ed.). Kennewick, WA, USA: Natural Products. pp. 81–83.  978-0-9614234-5-2. OCLC 32895480.
    3. Shulgin, Alexander; Shulgin, Ann (1997). "DMT is Everywhere". TiHKAL: The Continuation. United States: Transform Press. p. 277.  0-9630096-9-9. OCLC 38503252.
    4. Gallimore, Andrew R.; Strassman, Rick J. (2016). "A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience". Frontiers in Pharmacology. 7 (211). :10.3389/fphar.2016.00211.  1663-9812. PMC 4944667. PMID 27471468.
    5. Strassman, Rick J. (1995). "Human psychopharmacology of N,N-dimethyltryptamine". Behavioural Brain Research. 73 (1-2): 121–124. :10.1016/0166-4328(96)00081-2.  1872-7549.  0166-4328. OCLC 06183451.
    6. "Erowid DMT Vault: Basics". Erowid. August 22, 2000. Retrieved January 7, 2020.
    7. Lüscher, Christian; Ungless, Mark A. (2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11). :10.1371/journal.pmed.0030437.  1549-1277. PMID 17105338.
    8. Strassmann, Rick (1984). "Adverse reactions to psychedelic drugs. A review of the literature". Journal of Nervous and Mental Disease. 172 (10): 577–595. :10.1097/00005053-198410000-00001.  0022-3018. OCLC 1754691. PMID 6384428.
    9. "q21q21" (September 19, 2014). "Q21Q21 tek (and other limeteks) NOT recommended for shredded bark!". DMT Nexus. Retrieved January 8, 2020.
    10. Manske R. H. F. (1931). "A synthesis of the methyltryptamines and some derivatives". Canadian Journal of Research. 5 (5): 592–600. :10.1139/cjr31-097.  0366-6581.
    11. Bigwood J.; Ott J. (1977). "DMT: the fifteen minute trip". Head. 2 (4): 56–61. Archived from the original on January 27, 2006. Retrieved November 28, 2010.
    12. Strassman, R. J.; Qualls, C. R.; Uhlenhuth, E. H.; Kellner, R. (1994). "Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale" (PDF). Archives of General Psychiatry. 51 (2): 98–108. :10.1001/archpsyc.1994.03950020022002.  1538-3636.  2168-622X. PMID 8297217.
    13. Ott, Jonathan (1996). Pharmacotheon: Entheogenic Drugs, Their Plant Sources and History (2nd, densified ed.). Kennewick, WA: Natural Products.  978-0-9614234-9-0.
    14. Pachter I. J.; Zacharias D. E.; Ribeiro O. (1959). "Indole alkaloids of Acer saccharinum (the silver maple), Dictyoloma incanescens, Piptadenia colubrina, and Mimosa hostilis". The Journal of Organic Chemistry. 24 (9): 1285–87. :10.1021/jo01091a032.  1520-6904.  0022-3263.
    15. Fish M. S.; Johnson N. M.; Horning E. C. (1955). "Piptadenia alkaloids. Indole bases of P. peregrina (L.) Benth. and related species". Journal of the American Chemical Society. 72 (22): 5892–95. :10.1021/ja01627a034.  1520-5126.  0002-7863.
    16. Cimino G.; De Stefano S. (1978). "Chemistry of Mediterranean gorgonians: simple indole derivatives from Paramuricea chamaeleon". Comparative Biochemistry and Physiology C. 61 (2): 361–2. :10.1016/0306-4492(78)90070-9.
    17. https://www.erowid.org/chemicals/dmt/dmt_journal1.shtml
    18. Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; Ruoho, A. E. (2009). "The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator". Science. 323 (5916): 934–937. :10.1126/science.1166127.  1095-9203.  0036-8075. OCLC 1644869. PMC 2947205. PMID 19213917.
    19. Strassman, Rick J. (2001). DMT: The Spirit Molecule. A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences. Rochester, Vt: Park Street.  978-0-89281-927-0. OCLC 45195642. ("Chapter summaries". Retrieved 27 February 2012.)
    20. Nichols, David E. (2018). "N,N-dimethyltryptamine and the pineal gland: Separating fact from myth". Journal of Psychopharmacology. :10.1177/0269881117736919.  1461-7285.  0269-8811. OCLC 19962867. PMID 29095071.
    21. "'Mystical' psychedelic compound found in normal brains". Neuroscience News. June 27, 2019. Retrieved January 8, 2020.
    22. Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. :10.1016/j.celrep.2018.05.022.  2211-1247. PMID 29898390. PMC 6082376.
    23. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    24. "Convention On Psychotropic Substances, 1971" (PDF). United Nations Office on Drugs and Crime. Retrieved January 3, 2020.
    25. Herbert Schaepe (International Narcotics Control Board) (January 17, 2001). "International control of the preparation "ayahuasca"". Erowid. Retrieved January 8, 2020.
    26. "Poisons Standard December 2019". Federal Register of Legislation. Office of Parliamentary Counsel. November 14, 2019. Retrieved January 8, 2020.
    27. "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária [National Sanitary Surveillance Agency]. December 5, 2016. p. 22. Retrieved January 8, 2020.
    28. "Schedule III". Controlled Drugs and Substances Act (S.C. 1996, c. 19). Government of Canada. Retrieved January 1, 2020.
    29. "Bekendtgørelse om euforiserende stoffer - ni nye stoffer tilføjet" (in Danish). Danish Medicines Ageny. August 31, 2015. Retrieved January 1, 2020.
    30. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    31. "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (PDF). Bundesgesetzblatt Jahrgang 1974 Teil I Nr. 6 (in German). Bundesanzeiger Verlag. January 23, 1974. pp. 97–98. Retrieved January 7, 2020.
    32. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    33. "Tabella I" (PDF) (in Italian). Ministero della Salute [Ministry of Health]. p. 8. Retrieved January 7, 2020.
    34. "Schedule: Controlled Drugs". Misuse of Drugs Act, 1977. Government of Ireland. Retrieved January 8, 2020.
    35. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    36. "Opiumwet" (in Dutch). Ministerie van Binnenlandse Zaken en Koninkrijksrelaties [Ministry of the Interior and Kingdom Relations]. January 1, 2020. Retrieved January 8, 2020.
    37. "Schedule 1 Class A controlled drugs". "Reprint as at 13 August 2019: Misuse of Drugs Act 1975". Parliamentary Counsel Office. Retrieved January 7, 2020.
    38. "Постановление Правительства РФ от 30.06.1998 N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)" (in Russian). ГАРАНТ [GARANT]. Retrieved January 8, 2020.
    39. "Läkemedelsverkets författningssamling" (PDF) (in Swedish). Christina Rångemark Åkerman (Läkemedelsverket [Swedish Medical Products Agency]). September 21, 2011. p. 12.  1101-5225. Retrieved January 8, 2020.
    40. "Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved January 7, 2020.

    Resources

    1. 1717 CheMall HE040533
    2. 1717 CheMall HE170155
    3. 1717 CheMall HE379832
    4. abcr AB460938
    5. ACToR: Aggregated Computational Toxicology Resource 61-50-7
    6. AKos AKOS005446117
    7. Alfa Chemistry 61-50-7
    8. American Custom Chemicals Corp CHM0069872
    9. Angene AGN-PC-0JK7GQ
    10. ApexBio B7404
    11. Aurora Fine Chemicals A18.034.067
    12. Aurora Fine Chemicals K05.114.926
    13. Biosynth D-5500
    14. CambridgeSoft Corporation 2933
    15. Cayman Chemical 13959
    16. Cayman Chemical 13959.0
    17. Cayman Chemical 15694
    18. Cayman Chemical 15694.0
    19. ChEBI
    20. ChEBI CHEBI:28969
    21. ChemAdvisor OHS07780
    22. ChEMBL CHEMBL12420
    23. Chembo Pharma KB-296215
    24. ChemDB 4519410
    25. ChemDB 6750538
    26. ChemIDplus 000061507
    27. ChemIDplus 101831883
    28. ChemIDplus 61507
    29. Chemspace CSC015984723
    30. ChemSynthesis 20335
    31. Collaborative Drug Discovery 41408
    32. CSDeposition Service DB01488
    33. DiscoveryGate 4525689
    34. DiscoveryGate 58944
    35. DiscoveryGate 6089
    36. DrugBank DB01488
    37. DSigDB d4boss_662
    38. DSigDB d4ctd_5846
    39. DSigDB d4ttd_7603
    40. DTP/NCI 63795
    41. eMolecules 976831
    42. EPA DSSTox DTXCID4065313
    43. Erowid DMT
    44. FDA UNII - NLM UNII: WUB601BHAA
    45. FDA UNII - NLM WUB601BHAA
    46. Finetech Industry FT-0667348
    47. FooDB FDB023795
    48. Guide to PHARMACOLOGY 141
    49. Human Metabolome Database HMDB0005973
    50. Human Metabolome Database HMDB05973
    51. iChemical EBD21295
    52. Jean-Claude Bradley Open Melting Point Dataset 16741
    53. Jean-Claude Bradley Open Melting Point Dataset 21373
    54. Journal of Heterocyclic Chemistry 19660009_XXXVI
    55. KEGG C08302
    56. LabNetwork LN01288074
    57. Laboratory Chemical Safety Summary 6089
    58. LeadScope LS-82930
    59. MassBank JP003741
    60. MuseChem I010762
    61. NIAID 072305
    62. NIST Chemistry WebBook 1549698058
    63. NIST Spectra mainlib_352147
    64. NIST Spectra nist ri
    65. NIST Spectra replib_248091
    66. NIST Spectra replib_250700
    67. NIST Spectra replib_312935
    68. NIST Spectra replib_379568
    69. NIST Spectra replib_38693
    70. NMRShiftDB 10017644
    71. Parchem – fine & specialty chemicals 67379
    72. PubChem 6089
    73. PubMed 10090793
    74. PubMed 10350367
    75. PubMed 10372792
    76. PubMed 10404423
    77. PubMed 10438001
    78. PubMed 1057382
    79. PubMed 1057950
    80. PubMed 1058643
    81. PubMed 1059879
    82. PubMed 1062171
    83. PubMed 10637046
    84. PubMed 1064726
    85. PubMed 1066131
    86. PubMed 1067623
    87. PubMed 1068351
    88. PubMed 1069314
    89. PubMed 1070948
    90. PubMed 10940539
    91. PubMed 1095838
    92. PubMed 111285
    93. PubMed 11292011
    94. PubMed 11295326
    95. PubMed 116288
    96. PubMed 11763413
    97. PubMed 11900766
    98. PubMed 12361741
    99. PubMed 1275618
    100. PubMed 13384414
    101. PubMed 1354106
    102. PubMed 13685339
    103. PubMed 13914428
    104. PubMed 14138757
    105. PubMed 148665
    106. PubMed 15002845
    107. PubMed 15270248
    108. PubMed 15516287
    109. PubMed 15700647
    110. PubMed 15780487
    111. PubMed 16095048
    112. PubMed 16149327
    113. PubMed 16149328
    114. PubMed 16342002
    115. PubMed 16356341
    116. PubMed 16460788
    117. PubMed 16575552
    118. PubMed 17159796
    119. PubMed 17211054
    120. PubMed 17238112
    121. PubMed 17239595
    122. PubMed 17269042
    123. PubMed 17310474
    124. PubMed 17591658
    125. PubMed 1941365
    126. PubMed 1941625
    127. PubMed 2103707
    128. PubMed 2201522
    129. PubMed 22091
    130. PubMed 2268688
    131. PubMed 238721
    132. PubMed 266219
    133. PubMed 266950
    134. PubMed 267501
    135. PubMed 270770
    136. PubMed 271513
    137. PubMed 271755
    138. PubMed 276408
    139. PubMed 276891
    140. PubMed 278843
    141. PubMed 279544
    142. PubMed 279938
    143. PubMed 2828913
    144. PubMed 284199
    145. PubMed 284722
    146. PubMed 292978
    147. PubMed 3006089
    148. PubMed 329291
    149. PubMed 3350047
    150. PubMed 3455825
    151. PubMed 3472525
    152. PubMed 3472526
    153. PubMed 3475068
    154. PubMed 3481368
    155. PubMed 3489620
    156. PubMed 3801784
    157. PubMed 3858911
    158. PubMed 3866749
    159. PubMed 3867833
    160. PubMed 4041865
    161. PubMed 4056789
    162. PubMed 407597
    163. PubMed 41604
    164. PubMed 4196867
    165. PubMed 4358118
    166. PubMed 4517484
    167. PubMed 4518592
    168. PubMed 4519415
    169. PubMed 4520847
    170. PubMed 4527540
    171. PubMed 4533618
    172. PubMed 4582927
    173. PubMed 4607811
    174. PubMed 4696887
    175. PubMed 4927758
    176. PubMed 5031115
    177. PubMed 5053241
    178. PubMed 5064096
    179. PubMed 5077140
    180. PubMed 5081369
    181. PubMed 510375
    182. PubMed 5151243
    183. PubMed 5483205
    184. PubMed 5535408
    185. PubMed 5698438
    186. PubMed 5760624
    187. PubMed 5834159
    188. PubMed 5839067
    189. PubMed 5839429
    190. PubMed 6052683
    191. PubMed 6102916
    192. PubMed 6109775
    193. PubMed 6144308
    194. PubMed 6413999
    195. PubMed 6521493
    196. PubMed 6577915
    197. PubMed 6579573
    198. PubMed 6581313
    199. PubMed 6587171
    200. PubMed 6587850
    201. PubMed 6588281
    202. PubMed 6641790
    203. PubMed 6769527
    204. PubMed 6770869
    205. PubMed 6793698
    206. PubMed 6798607
    207. PubMed 6798611
    208. PubMed 7005
    209. PubMed 7086824
    210. PubMed 731434
    211. PubMed 7905222
    212. PubMed 7905821
    213. PubMed 803203
    214. PubMed 8297216
    215. PubMed 8297217
    216. PubMed 9447860
    217. PubMed 9468359
    218. PubMed 9682278
    219. PubMed 9768567
    220. PubMed 9852119
    221. Royal Society of Chemistry b9nj00577c
    222. Royal Society of Chemistry c1md00044f
    223. RSC Learn Chemistry Wiki N,N-Dimethyltryptamine
    224. Sabio-RK 10401
    225. Serum Metabolome Database HMDB0005973
    226. Sigma-Aldrich CERILLIAN-D-102
    227. Sigma-Aldrich D-102
    228. Sigma-Aldrich SIGMA-SML0791
    229. Sigma-Aldrich SML0791
    230. SORD SST0049979
    231. Springer Nature 5-HT agonist induced analgesia modulated by central but not peripheral noradrenaline depletion in rats
    232. Springer Nature A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity
    233. Springer Nature A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 ??-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches
    234. Springer Nature Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users
    235. Springer Nature Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors
    236. Springer Nature An observational study of hallucinogen-induced behavior in unrestrained Macaca mulatta
    237. Springer Nature Ayahuasca and Kambo intoxication after alternative natural therapy for depression, confirmed by mass spectrometry
    238. Springer Nature Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
    239. Springer Nature Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015
    240. Springer Nature Behavioral effects of ??,??,??,??-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor
    241. Springer Nature Biological activities of some 5-substituted N,N-dimethyltryptamines, ??-methyltryptamines, and gramines
    242. Springer Nature Blood and urine levels of N,N-dimethyltryptamine following administration of psychoactive dosages to human subjects
    243. Springer Nature Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al.
    244. Springer Nature Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man
    245. Springer Nature Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats
    246. Springer Nature Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers
    247. Springer Nature Dimethyltryptamin: Its metabolism in man; the relation of its psychotic effect to the serotonin metabolism
    248. Springer Nature Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter
    249. Springer Nature Dimethyltryptamine levels in blood of schizophrenic patients and control subjects
    250. Springer Nature Discriminative stimulus effects of N,N-diisopropyltryptamine
    251. Springer Nature Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively
    252. Springer Nature Effects of pargyline and SKF-525A on brain N,N-dimethyltryptamine concentrations and hyperactivity in mice
    253. Springer Nature Effects of psychotropic drugs on open-field behaviour in rats
    254. Springer Nature Effects of selected opioid agonists and antagonists on DMT-and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat
    255. Springer Nature Electroencephalographic studies on the development of tolerance and cross tolerance to mescaline in the rat
    256. Springer Nature Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities
    257. Springer Nature Factors affecting the urinary excretion of endogenously formed dimethyltryptamine in normal human subjects
    258. Springer Nature Gas chromatographic-mass spectrometric isotope dilution determination of N,N-dimethyltryptamine concentrations in normals and psychiatric patients
    259. Springer Nature Hallucinogenic agents as discriminative stimuli: A correlation with serotonin receptor affinities
    260. Springer Nature Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
    261. Springer Nature High specific activity tritium labelling of some sigma-1 receptor agonists
    262. Springer Nature High-affinity 3H-serotonin binding to caudate: Inhibition by hallucinogens and serotoninergic drugs
    263. Springer Nature Hydroxylation and N-demethylation of N,N-dimethyltryptamine
    264. Springer Nature Immunohistochemical and behavioral analysis of spinal lesions induced by a substance P antagonist and protection by thyrotropin releasing hormone
    265. Springer Nature In vivo kinetics and displacement study of a carbon-11-labeled hallucinogen, N,N-[11C]dimethyltryptamine
    266. Springer Nature Increased frontal and paralimbic activation following ayahuasca, the pan-amazonian inebriant
    267. Springer Nature Interaction of synthetic opioid metenkephalin peptide analogs, lilly 127623 and FK 33-824 with indole hallucinogens: Antagonism of N,N-dimethyltryptamine- and LSD-induced disruption of food-rewarded bar pressing behavior in the rat
    268. Springer Nature LDH isoenzyme spectrum in the myocardium of rats after repeated doses of isoproterenol
    269. Springer Nature Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro
    270. Springer Nature Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
    271. Springer Nature Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
    272. Springer Nature Myo-inositol attenuates the enhancement of the serotonin syndrome by lithium
    273. Springer Nature N-dimethylated indoleamines in blood of acute schizophrenics
    274. Springer Nature Naloxone enhancement of DMT and LSD-25 induced suppression of food-rewarded bar pressing behavior in the rat
    275. Springer Nature Neurochemical investigations of the interaction of N,N-dimethyltryptamine with the dopaminergic system in rat brain
    276. Springer Nature Neurotheologie
    277. Springer Nature New fluorophore-forming reactions for histochemical visualization of N-acetylated and tertiary indolamines using glyoxylic acid, aluminum-formaldehyde and trifluoroacetic acid anhydride as reagents
    278. Springer Nature On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis
    279. Springer Nature Pharmacological evidence of neuro-pharmacological activity of Acacia tortilis leaves in mice
    280. Springer Nature Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis
    281. Springer Nature Pharmacology of ayahuasca administered in two repeated doses
    282. Springer Nature Phenelzine withdrawal
    283. Springer Nature Platelet serotonin uptake sites increased in drinkers ofayahuasca
    284. Springer Nature Receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart
    285. Springer Nature Relative potency of amphetamine derivatives and N,N-dimethyltryptamines
    286. Springer Nature Severe aggression in rats induced by mescaline but not other hallucinogens
    287. Springer Nature Stimulation of rat prolactin secretion by indolealkylamine hallucinogens
    288. Springer Nature Structure activity relations of some indolealkylamines in comparison to phenethylamines on motor activity and acquisition of avoidance behavior
    289. Springer Nature Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
    290. Springer Nature Substituierte t-Hexylamine als neuer Typ hypotensiv wirksamer Verbindungen
    291. Springer Nature Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report
    292. Springer Nature The effect of MAO inhibition on the experimental psychosis induced by dimethyltryptamin
    293. Springer Nature The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide
    294. Springer Nature The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ
    295. Springer Nature The effects of N,N-dimethyltryptamine on operant behavior in squirrel monkeys
    296. Springer Nature The hallucinogenic world of tryptamines: an updated review
    297. Springer Nature The inhibition of the cage-leaving responseu2014A model for studies of the serotonergic neurotransmission in the rat
    298. Springer Nature The psychedelic properties of banana peel: an appraisal
    299. Springer Nature The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice
    300. Springer Nature Vergleich ver??nderter Bewu??tseinszust??nde unter den Halluzinogenen (???)-??9-trans-Tetrahydrocannabinol (??9-THC) und N,N-Dimethyltryptamin (DMT)
    301. SynQuest 3H32-1-0R
    302. The Merck Index Online cs000000007449
    303. Thieme Chemistry SD-110-00020
    304. Thomson Pharma 00483902
    305. Thoreauchem TH-B00149
    306. Tocris Bioscience 3428
    307. Tractus Company Limited
    308. Urine Metabolome Database HMDB0005973
    309. VulcanChem VC009379
    310. Wikidata Q407217
    311. Wikipedia Dimethyltryptamine
    312. Wikipedia N,N-Dimethyltryptamine
    313. xPharm 9015
    314. ZINC ZINC00897457

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.